GRPR and prostate carcinoma: We have earlier reported the preclinical [30] and clinical [32] evaluation of the GRPR antagonist-based tracer [99mTc]Tc-maSSS-PEG2-RM26 aimed, first and foremost, at the staging of prostate cancer.